Replies to post #22505 on Biotech Values

[DewDiligence]

Re: ADH Eniluracil

>Do you consider eniluracil a long shot because of history of failed trials. Part of the attraction for me of ADH is the simplicity of there argument for why there approach should work.<

The new approach is relatively simple to explain, but it may be hard to implement. The drug ratio that works best for one patient may not be optimal for another; hence, showing clinically meaningful efficacy in a heterogeneous setting could be a nettlesome task.

I consider Eniluracil the icing on the ADH cake rather than the cake itself. Regards, Dew